Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) traded up 0.3% during trading on Monday . The stock traded as high as $102.46 and last traded at $101.85, 77,862 shares were traded during trading. A decline of 89% from the average session volume of 678,702 shares. The stock had previously closed at $101.57.
A number of analysts recently issued reports on ALNY shares. Evercore ISI started coverage on Alnylam Pharmaceuticals in a research report on Friday, February 7th. They set a “buy” rating and a $145.00 price objective for the company. Cowen reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, March 5th. Barclays raised their price objective on Alnylam Pharmaceuticals from $125.00 to $131.00 and gave the stock an “overweight” rating in a research report on Thursday, November 21st. BidaskClub raised Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Finally, Needham & Company LLC reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $128.89.
The company has a market capitalization of $11.43 billion, a price-to-earnings ratio of -12.08 and a beta of 2.22. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 4.87. The firm has a 50-day simple moving average of $118.62 and a two-hundred day simple moving average of $104.30.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 6th. The biopharmaceutical company reported ($2.47) earnings per share for the quarter, missing the consensus estimate of ($2.25) by ($0.22). The firm had revenue of $71.70 million during the quarter, compared to analyst estimates of $71.45 million. Alnylam Pharmaceuticals had a negative net margin of 403.24% and a negative return on equity of 55.82%. The business’s revenue was up 241.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.82) earnings per share. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -7.2 EPS for the current fiscal year.
In other Alnylam Pharmaceuticals news, COO Yvonne Greenstreet sold 9,892 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $130.00, for a total value of $1,285,960.00. Following the completion of the transaction, the chief operating officer now directly owns 12,458 shares of the company’s stock, valued at approximately $1,619,540. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO John Maraganore sold 34,765 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $131.85, for a total value of $4,583,765.25. Following the completion of the transaction, the chief executive officer now directly owns 224,758 shares of the company’s stock, valued at $29,634,342.30. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 151,989 shares of company stock valued at $19,091,758. 3.60% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp grew its position in shares of Alnylam Pharmaceuticals by 3.7% during the third quarter. State Street Corp now owns 3,001,157 shares of the biopharmaceutical company’s stock worth $241,353,000 after buying an additional 108,000 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Alnylam Pharmaceuticals by 4.3% during the fourth quarter. Geode Capital Management LLC now owns 1,239,487 shares of the biopharmaceutical company’s stock worth $142,622,000 after buying an additional 50,788 shares in the last quarter. Norges Bank acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $115,540,000. UBS Asset Management Americas Inc. grew its position in shares of Alnylam Pharmaceuticals by 4.1% during the fourth quarter. UBS Asset Management Americas Inc. now owns 823,669 shares of the biopharmaceutical company’s stock worth $94,862,000 after buying an additional 32,360 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Alnylam Pharmaceuticals by 1.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 600,778 shares of the biopharmaceutical company’s stock worth $69,192,000 after buying an additional 9,278 shares in the last quarter. 93.91% of the stock is owned by institutional investors.
Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company’s pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
